Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight SK Life Science Labs unveiled new AACR 2026 preclinical data on p300 and PRMT5 degraders. Read why this oncology strategy could matter next. byVenkateshApril 18, 2026